Astria Therapeutics receives FDA Orphan Drug Designation for navenibart to treat hereditary angioedema.

Astria Therapeutics has obtained FDA Orphan Drug Designation for navenibart, aimed at treating hereditary angioedema, a rare genetic disorder causing severe tissue swelling. This designation facilitates development and offers extended marketing exclusivity. Phase 1b/2 study results indicated a 90-96% reduction in attack rates over six months. The company plans to release more data later this year and initiate a Phase 3 trial in early 2025.

September 30, 2024
3 Articles